Curasight A/S (NGM:CURAS)

Market Cap	1.51B +1,863.8%
Revenue (ttm)	n/a
Net Income	-93.01M
EPS	-1.69
Shares Out	48.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,946
Open	20.40
Previous Close	20.00
Day's Range	20.40 - 21.90
52-Week Range	1.95 - 25.00
Beta	0.43
Analysts	n/a
Price Target	8.00 (-63.3%)
Earnings Date	May 28, 2026

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. The company develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. It is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 15, 2026

Data Sources Report a data error